We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RPRX market cap is 18.3B. The company's latest EPS is USD 1.9261 and P/E is 16.12.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 543.61M | 473.57M | 567.98M | 583.49M | 622.37M |
| Operating Income | 153.52M | 468.93M | -87.92M | 317.55M | 803.16M |
| Net Income | 72.11M | 494.34M | 4.78M | 102M | 543.99M |
| Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 2.12B | 2.29B | 2.24B | 2.35B |
| Operating Income | -13.79M | 1.64B | 1.41B | 913.92M | 1.5B |
| Net Income | 51.28M | 975.04M | 619.73M | 42.83M | 1.13B |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 15.86B | 16.38B | 16.13B | 17.66B | 18.04B |
| Total Liabilities | 6.27B | 6.3B | 6.27B | 7.9B | 7.78B |
| Total Equity | 9.59B | 10.08B | 9.86B | 9.75B | 10.26B |
| Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 15.07B | 16.02B | 17.52B | 16.81B | 16.38B |
| Total Liabilities | 10.03M | 6.12B | 7.27B | 7.29B | 6.3B |
| Total Equity | 15.06B | 9.9B | 10.25B | 9.53B | 10.08B |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 2.22B | 2.99B | 664.64M | 1.32B | 2.03B |
| Investing | -1.07B | -2.07B | -86.65M | -979.83M | -2.17B |
| Financing | -1.92B | -2.15B | -212M | 944.61M | 619.11M |
| Year End 31 December 2023 | 2020 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 45.61M | 2.03B | 2.02B | 2.14B | 2.99B |
| Investing | -1.87B | -2.76B | -1.87B | -1.03B | -2.07B |
| Financing | 1.91B | 1.49B | 385.11M | -944.86M | -2.15B |
| Market Cap | 18.3B |
| Price to Earnings Ratio | 16.12 |
| Price to Sales Ratio | 7.77 |
| Price to Cash Ratio | 38.35 |
| Price to Book Ratio | 1.81 |
| Dividend Yield | 2.83% |
| Shares Outstanding | 589.18M |
| Average Volume (1 week) | 3.04M |
| Average Volume (1 Month) | 3.57M |
| 52 Week Change | 5.54% |
| 52 Week High | 31.655 |
| 52 Week Low | 24.05 |
| Spread (Intraday) | 0.89 (2.85%) |
| Company Name | Royalty Pharma PLC |
| Address |
the pavilions bridgwater road bristol BS13 8AE |
| Website | https://www.royaltypharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
